DGX - Quest Diagnostics Incorporated
NYSE
->
Healthcare
->
Diagnostics & Research
Secaucus,
United States
Type: Equity
DGX price evolution
DGX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $271 | $474 | $686 | |
| Short term investments | ||||
| Net receivables | $1376 | $1319 | $1322 | $1210 |
| Inventory | $184 | $182 | $181 | $190 |
| Total current assets | $2623 | $2017 | $2228 | $2372 |
| Long term investments | $126 | $133 | $135 | |
| Property, plant & equipment | $2754 | $2435 | $2389 | $2418 |
| Goodwill & intangible assets | $9087 | $9022 | $8899 | |
| Total noncurrent assets | $11864 | $11726 | $11650 | |
| Total investments | $126 | $133 | $135 | |
| Total assets | $16095 | $13881 | $13954 | $14022 |
| Current liabilities | ||||
| Accounts payable | $1313 | $1247 | $1239 | $1359 |
| Deferred revenue | ||||
| Short long term debt | $765 | $1059 | $456 | |
| Total current liabilities | $2092 | $2012 | $2298 | $1815 |
| Long term debt | $5648 | $4323 | $4293 | $4410 |
| Total noncurrent liabilities | $5213 | $5187 | $5865 | |
| Total debt | $5088 | $5352 | $5369 | |
| Total liabilities | $9286 | $7225 | $7485 | $7715 |
| Shareholders' equity | ||||
| Retained earnings | $9222 | $9080 | $8935 | $8825 |
| Other shareholder equity | -$15 | -$19 | -$16 | -$14 |
| Total shareholder equity | $6617 | $6432 | $6307 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $686 | $315 | $872 | $1158 |
| Short term investments | ||||
| Net receivables | $1210 | $1195 | $1438 | $1520 |
| Inventory | $190 | $192 | $208 | $223 |
| Total current assets | $2372 | $1898 | $2741 | $3058 |
| Long term investments | $135 | $132 | $141 | $521 |
| Property, plant & equipment | $2418 | $2351 | $2304 | $2231 |
| Goodwill & intangible assets | $8899 | $8312 | $8262 | $8040 |
| Total noncurrent assets | $11650 | $10939 | $10870 | $10968 |
| Total investments | $135 | $132 | $141 | $521 |
| Total assets | $14022 | $12837 | $13611 | $14026 |
| Current liabilities | ||||
| Accounts payable | $1359 | $1396 | $1600 | $1633 |
| Deferred revenue | ||||
| Short long term debt | $456 | $155 | $153 | $143 |
| Total current liabilities | $1815 | $1551 | $1753 | $1776 |
| Long term debt | $4410 | $3978 | $4504 | $4512 |
| Total noncurrent liabilities | $5865 | $5356 | $5375 | $5441 |
| Total debt | $5369 | $4622 | $4657 | $4655 |
| Total liabilities | $7715 | $6944 | $7128 | $7217 |
| Shareholders' equity | ||||
| Retained earnings | $8825 | $8290 | $7649 | $9303 |
| Other shareholder equity | -$14 | -$21 | -$14 | -$21 |
| Total shareholder equity | $6307 | $5893 | $6444 | $6759 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2488 | $2397 | $2366 | $2288 |
| Cost of revenue | $1593 | $1595 | ||
| Gross Profit | $816 | $804 | $771 | $740 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $416 | $440 | ||
| Total operating expenses | $466 | $449 | $471 | $462 |
| Operating income | $355 | $300 | ||
| Income from continuing operations | ||||
| EBIT | $347 | $303 | ||
| Income tax expense | $65 | $74 | $66 | $40 |
| Interest expense | -$34 | $44 | $43 | -$40 |
| Net income | ||||
| Net income | $225 | $229 | $194 | $192 |
| Income (for common shares) | $229 | $194 | ||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9252 | $9883 | $9437 | |
| Cost of revenue | $6450 | $5804 | ||
| Gross Profit | $3069 | $3433 | $3633 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $1874 | $1550 | ||
| Total operating expenses | $1764 | $2005 | $1662 | |
| Operating income | $1428 | $1971 | ||
| Income from continuing operations | ||||
| EBIT | $1348 | $2054 | ||
| Income tax expense | $248 | $264 | $460 | |
| Interest expense | -$152 | $138 | $163 | |
| Net income | ||||
| Net income | $850 | $946 | $1431 | |
| Income (for common shares) | $946 | $1431 | ||
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | $229 | $194 | ||
| Operating activities | ||||
| Depreciation | $117 | $116 | ||
| Business acquisitions & disposals | -$106 | -$142 | ||
| Stock-based compensation | $20 | $22 | ||
| Total cash flows from operations | $360 | $154 | ||
| Investing activities | ||||
| Capital expenditures | -$92 | -$104 | ||
| Investments | ||||
| Total cash flows from investing | -$2046 | -$200 | -$213 | -$1061 |
| Financing activities | ||||
| Dividends paid | -$247 | -$84 | -$79 | -$314 |
| Sale and purchase of stock | $16 | $12 | ||
| Net borrowings | -$301 | |||
| Total cash flows from financing | $1254 | -$363 | -$153 | $160 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $78 | -$203 | -$212 | $371 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $946 | $1995 | $1431 | |
| Operating activities | ||||
| Depreciation | $437 | $408 | $361 | |
| Business acquisitions & disposals | -$144 | $424 | -$330 | |
| Stock-based compensation | $77 | $79 | $97 | |
| Total cash flows from operations | $1718 | $2233 | $2005 | |
| Investing activities | ||||
| Capital expenditures | -$404 | -$400 | -$415 | |
| Investments | $5 | -$3 | -$27 | |
| Total cash flows from investing | -$1061 | -$543 | $21 | -$772 |
| Financing activities | ||||
| Dividends paid | -$314 | -$305 | -$309 | -$297 |
| Sale and purchase of stock | -$1285 | -$2070 | -$136 | |
| Net borrowings | -$2 | -$2 | -$805 | |
| Total cash flows from financing | $160 | -$1732 | -$2540 | -$1267 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $371 | -$557 | -$286 | -$34 |
News
|
Quest Diagnostics Q4 Earnings Preview: What's in Store for the Stock?
Zacks · via Yahoo Finance
23 Jan 2025
|
|
Why Quest Diagnostics Incorporated (DGX) Is One of the Most Undervalued Pot...
Insider Monkey · via Yahoo Finance
28 Nov 2024
|
|
Quest Diagnostics (DGX) Up 2.7% Since Last Earnings Report: Can It Continue?
Zacks · via Yahoo Finance
21 Nov 2024
|
|
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up
Zacks
10 Nov 2024
|
|
AMN Stock Falls Despite Q3 Earnings & Revenues Beat, Margins Contract
Zacks
8 Nov 2024
|
|
BDX Stock Gains Following Q4 Earnings Beat and Higher Margins
Zacks
7 Nov 2024
|
|
CLOV Stock Declines Despite Q3 Earnings Beat, FY24 View Revised
Zacks
7 Nov 2024
|
|
Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised
Zacks
6 Nov 2024
|
|
INSP Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
Zacks
4 Nov 2024
|
|
Is Quest Diagnostics Incorporated (DGX) an Undervalued High Growth Stock?
Insider Monkey · via Yahoo Finance
23 Jul 2024
|
Fundamentals
| Market cap | $17.39B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 112.00M |
| Revenue | $9.54B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $840.00M |
| Revenue Q/Q | 8.41% |
| Revenue Y/Y | 2.60% |
| P/E ratio | 20.70 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.82 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $7.50 |
|---|---|
| ROA | 5.80% |
| ROE | N/A |
| Debt/Equity | 1.22 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.25 |
| Quick ratio | 1.17 |